NCT07038876Phase 2Completed

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Study sponsor: MapLight Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-06-04Actual
Enrollment · participants307Actual
Source updated2026-07-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Aug 2026. After: 4 Jun 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 300 participants (planned). After: 307 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 1 field changed

Primary completion date changed

Before: Jan 2027. After: Aug 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview